Medical technology company Ypsomed will supply Lifescan with needles needed for insulin pen systems. The company did not provide any information about the delivery volume.
As a result, an additional manufacturing facility for needles was built within the Solothurn factory. In the first half of 2012/13 about CHF 8m were spent with regards to extending needle manufacturing. When French key account Sanovis exited last year Ypsomed diversified its products and services. The company invested heavily in the development of new pen needles. To some extent, deficits due to missing orders could be unwinded by acquiring new customers. However, in the first half of 2012 the company again reported decreasing sales.
[ilink url=“http://www.nzz.ch/aktuell/startseite/-1.17860946″] Link to source (Neues Zürcher Zeitung)[/ilink]